A comparison of the treatment groups with a similar group of patients receiving no treatment for bone loss indicates both treatments help prevent bone loss . However, significantly more of the calcitriol patients than the alendronate patients -- 27 percent vs. 7 percent -- also developed a condition known as hypercalciuria, which is excessive loss of calcium in the urine
Thus based on these studies researchers conclude that alendronate is the better treatment for bone loss among people who have undergone a heart transplant.